hmey Preclinical Testing Services,
Inc. has assembled a world-class physician and researcher advisory board
for its Cardionomics(TM) Services. All Cardionomics(TM) Advisory Board
members are highly-sought after scientists with vast experience and
significant industry and academic excellence, as well as specialized
expertise in running clinical trials. Furthermore, the panel members have
taken concepts from the bench side all the way to clinical trials and
therefore have extensive experience in navigating the FDA field.
"The Cardionomics Services and Advisory Board provide a unique approach
and solution to prevent new drugs from posing cardiac risk. This kind of
original and innovative thinking is typical of Dr. Gwathmey, who has been
at the forefront of heart failure research for over 20 years," said Michael
Bristow, M.D., Ph.D. founder of Myogen, and founder and CEO of ARCA
Gwathmey Preclinical Testing Services, Inc. Cardionomics(TM) Advisory
Board Members include:
Gary Francis, M.D.
Section Head, Clinical Cardiology
Roger J. Hajjar, M.D.
Professor, Medicine / Cardiology Professor
Mt. Sinai Department of Gene and Cell Medicine
Barry M. Massie, M.D., F.A.C.C.
Chief, Cardiology Division
University of California, San Francisco
Michael Rosen, M.D.
Professor of Pharmacology and Pediatrics
Columbia University College of Physicians and Surgeons
Stephen F. Vatner, M.D.
Chair, Cell Biology and Molecular Medicine, Professor
University of Medicine and Dentistry of New Jersey
About Gwathmey Preclinical Testing Services, Inc.
Gwathmey Preclinical Testing Services, Inc. supports biotechnology and
pharmaceutical companies to meet their scientific and financial goals
through a disciplined approach that maximizes quality, throughput and
process efficiency. We are continually performing process improvement,
Page: 1 2 3 4 Related biology technology :1
|SOURCE Gwathmey Preclinical Testing Services, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines2
. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)3
. Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 20074
. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin5
. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.6
. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price7
. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease8
. District Judge Dismisses Shareholder Suit Related to Boston Scientific9
. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)10
. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)11
. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders